Questions List

Hello YOU NEED FAST PROXY SERVERS ? Check it out this Anonymous and Private Proxy Servers. - HTTP & SOCKS5 Proxy supported. - IP Authentication or Password Authentication available. - MORE INFO HERE: https://bit.ly/3ifZkmL Thanks, Douglas Wootton If you no longer wish to hear from us, please reply this email.Posted onFebruary 10, 2021 1:21 am

Hello YOU NEED QUALITY VISITORS FOR YOUR: cme-congresses.com ? WE PROVIDE HIGH-QUALITY VISITORS WITH: - 100% safe for your site - real visitors with unique IPs. No bots, proxies, or datacenters - visitors from Search Engine (by keyword) - visitors from Social Media Sites (referrals) - visitors from any country you want (USA/UK/CA/EU…) - very low bounce rate - very long visit duration - multiple pages visited - tractable in google analytics - custom URL tracking provided - boost ranking in SERP, SEO, profit from CPM CLAIM YOUR 24 HOURS FREE TEST HERE=> ventfara@mail.com Thanks, Taylah SnowPosted onJanuary 27, 2021 4:45 am

Posted onJanuary 11, 2021 11:24 am

Hello YOU NEED QUALITY VISITORS FOR YOUR: cme-congresses.com WE PROVIDE ORGANIC VISITORS BY KEYWORD FROM SEARCH ENGINES OR SOCIAL MEDIA YOU GET HIGH-QUALITY VISITORS - visitors from search engines - visitors from social media - visitors from any country you want CLAIM YOUR 24 HOURS FREE TEST => https://bit.ly/2HQZggh Thanks, Samara Gillingham If you no longer wish to hear from us, please reply this email.Posted onDecember 30, 2020 12:10 pm

Posted onDecember 27, 2020 6:50 pm

Posted onDecember 1, 2020 11:11 am

YOU NEED QUALITY VISITORS for your: cme-congresses.com YOU GET HIGH-QUALITY VISITORS - visitors from search engines - visitors from social media - visitors from any country you want - very low bounce rate & long visit duration CLAIM YOUR 24 HOURS FREE TEST => http://bit.ly/GetTrafficSmart Posted onNovember 2, 2020 8:18 am

Posted onOctober 24, 2020 7:29 am

aPosted onOctober 14, 2020 11:30 am

Posted onOctober 14, 2020 11:30 am

NznaPosted onOctober 12, 2020 5:11 pm

asdfsadfPosted onOctober 8, 2020 4:28 pm

jhkjklfasdhjklfhljkashlflasjdPosted onOctober 8, 2020 4:27 pm

helloPosted onOctober 8, 2020 4:27 pm

Posted onOctober 8, 2020 4:04 pm

TestPosted onOctober 8, 2020 3:57 pm

Posted onOctober 7, 2020 8:10 pm

Posted onOctober 4, 2020 7:37 pm

Thank you! Bye!Posted onOctober 4, 2020 5:34 pm

Posted onOctober 4, 2020 5:32 pm

Co-My is a great event and concentrates on myeloma outside IMW which is every 2 years and this is twice a year, real feast Mamta GargPosted onOctober 4, 2020 5:32 pm

Congratulations to you Prof Mohty, you were fabulous mamta GargPosted onOctober 4, 2020 5:32 pm

Would u do second auto sct for relapsed post dara based regimen in less than 12 m post first auto . To help better mrd achievement? Posted onOctober 4, 2020 5:16 pm

DVdPosted onOctober 4, 2020 5:09 pm

Treatment free monitoringPosted onOctober 4, 2020 5:05 pm

sorry, i don't get poll optionPosted onOctober 4, 2020 5:04 pm

Posted onOctober 4, 2020 5:00 pm

Thank you! amazing event as usualPosted onOctober 4, 2020 4:15 pm

Posted onOctober 4, 2020 4:09 pm

Professor Mohty, I would respectfully suggest quoting the following phrase stated by Professor Giampaolo a few minutes ago in the COMy site: "I made my little contribution, but it was really the community who did it". Prof. Giampaolo Merlini, October 4th, 2020. Thank you! Kind regards, Antonio Macedo (Brazil)Posted onOctober 4, 2020 4:01 pm

Impressive the dedication of Dr Merlini ThanKs You are an example for us Posted onOctober 4, 2020 3:50 pm

Thank you, Professor! Posted onOctober 4, 2020 3:47 pm

Any robust evidence for the role of doxycycline for the management of cardiac involvement in AL amyloidosis?Posted onOctober 4, 2020 3:44 pm

Congratulations SaadPosted onOctober 4, 2020 3:17 pm

Posted onOctober 4, 2020 3:07 pm

Thank you Dr Usmani!!!!Posted onOctober 4, 2020 3:07 pm

Thank you Dr Usmani!!!!Posted onOctober 4, 2020 3:07 pm

Posted onOctober 4, 2020 2:55 pm

Congrats Dr Saad Usmani - You are a great speaker and have contributed significantly to the improvement of clinical management of Multiple Myeloma. You deserve this!Posted onOctober 4, 2020 2:54 pm

Thank you!Posted onOctober 4, 2020 2:40 pm

At ASH there was data that the stroma may play an important role in resistance to CAR-T cells. Should we be targeting the abnormal MM stroma to improve CAR-T cell function and persistence?Posted onOctober 4, 2020 2:34 pm

What about using CAR-NK cells in the future as a more convenient allo approach?Posted onOctober 4, 2020 2:18 pm

Taking the effect on T cell with anti CD38, is ther a rational to combine anti CD38 with either CAR-T or bi-specific Posted onOctober 4, 2020 2:13 pm

Apart from down modulation or loss of BCMA what factors do you think are most important in leading to CAR-T cell resistance?Posted onOctober 4, 2020 2:09 pm

Test test testPosted onOctober 4, 2020 1:45 pm

Merci!Posted onOctober 4, 2020 1:29 pm

What relapse drugs would you consider in a patient who had severely elevated liver enzymes during induction VCD. Avoided rechallenge with PI, and switched to Dara-RD induction, followed by ASCT.Posted onOctober 4, 2020 1:27 pm

Do you see that there are genetic alterations ( from low risk to high risk) when pt is on certain classes of drugs? Thank youPosted onOctober 4, 2020 1:24 pm

would the panel comment on the best partner for melflufen? Posted onOctober 4, 2020 1:07 pm

Is Dara resistance not due more to macrophage polarisation and T cell exhaustion than due to CD38 down regulation?Posted onOctober 4, 2020 1:02 pm

In case of Dara failure (not primary), what about giving Dara once weekly, as in the induction? Posted onOctober 4, 2020 12:56 pm

Posted onOctober 4, 2020 12:54 pm

Posted onOctober 4, 2020 12:54 pm

Don't forger evaluation ! thanksPosted onOctober 4, 2020 11:59 am

there is at least one clinical trial to retreat with abMo (Lynx trial): dara sq Kd vs KdPosted onOctober 4, 2020 11:48 am

What about venetoclax in 11;14. In my opinion the earlier you use the better.Posted onOctober 4, 2020 11:38 am

What about venetoclax in 11;14. In my opinion the earlier you use the better.Posted onOctober 4, 2020 11:38 am

Which MoAB is more interesting in RRMM after Dara ineffectiveness: Isa or Elo?Posted onOctober 4, 2020 11:35 am

the patient is "the owner" of the disease and for the treatment: have to be in the center of decision (my point of view) Posted onOctober 4, 2020 11:22 am

Dr Moreau If there is a early biochemical relapse in a patient who is off therapy - would you wait for symptoms or intervene with a doublet like Pd to prevent a formal relapse rather than a 3 drug regimen?Posted onOctober 4, 2020 11:14 am

Dr Mateos Does POM work in the extramedullary disease also ?Posted onOctober 4, 2020 10:57 am

Posted onOctober 4, 2020 10:48 am

Posted onOctober 4, 2020 10:48 am

Dr Thiery Facon - where would you place bendamustine in relapsed myeloma - earlier or later ? alone or in combination?Posted onOctober 4, 2020 10:46 am

Very clear presentationPosted onOctober 4, 2020 10:44 am

question for Dr Jakubowiak: Can you comment on the lower doses of CAR-T cells used in this study compared with other BCMA CAR-T studies?Posted onOctober 4, 2020 9:54 am

Dear Paul thanks for this excellent presentation. I recently noticed there are different definitions of EMD across studies (e.g. soft tissue only versus EMD extending from bone lesions). How should EMD be best defined according to your opinion? Posted onOctober 4, 2020 9:42 am

What is the future for NDMM and RRMM? What are you most excited about Posted onOctober 4, 2020 9:40 am

was the toxicity laboratory or TEAE? Posted onOctober 4, 2020 9:08 am

How many cell / % of cells had to be positive to define high risk ? Posted onOctober 4, 2020 8:49 am

This is CME accredited medical conference. Why is blocked?Posted onOctober 4, 2020 8:38 am

need clinical trial based on frailty: modified schedule vs SOC...?? Posted onOctober 4, 2020 8:20 am

But what about Len and new neoplasms risk?Posted onOctober 4, 2020 8:07 am

What is the best treatment option for ederly patients with renal failure? Thank youPosted onOctober 4, 2020 8:06 am

How about instead of fraility assessement building up treadment from low dose to higher dose if tolerated in case of the frailers? Posted onOctober 4, 2020 7:59 am

Is VRd can be the regimen that fit them all?Posted onOctober 4, 2020 7:59 am

According to the published data what is you oppinion about denosumad and its possibility to impove PFS in older MM patients?Posted onOctober 4, 2020 7:46 am

MRD (-) status: whether it is may be an aim of older MM patients treatment?Posted onOctober 4, 2020 7:45 am

To Sonja Zweegman: is it possible that less steroid is good for all patients and not only the frail ones. ThanksPosted onOctober 4, 2020 7:27 am

Posted onOctober 4, 2020 7:27 am

********************** DAY 2 (above this line) ********************************Posted onOctober 4, 2020 6:27 am

Posted onOctober 4, 2020 3:24 am

Posted onOctober 3, 2020 7:48 pm

Posted onOctober 3, 2020 6:50 pm

Posted onOctober 3, 2020 6:47 pm

Bravo merciPosted onOctober 3, 2020 6:34 pm

❤️❤️❤️❤️ to xavierPosted onOctober 3, 2020 6:34 pm

Congratulations congratulations congratulations Great idea GSK Posted onOctober 3, 2020 6:34 pm

To both speakers. Why we never have head to head comparisons between these end stage drugs?Posted onOctober 3, 2020 6:33 pm

Is there any merit in giving belantamab less frequently to avoid keratopathy? Thanks Posted onOctober 3, 2020 6:32 pm

I love this symposium although I have never prescribed this antibody.Posted onOctober 3, 2020 6:32 pm

COMY is the best myeloma congress ever. It is the only congress where we have these important debates and questions. Thank you for this excellent sessionPosted onOctober 3, 2020 6:29 pm

Selenixor cause significant thrombocytopenia and patient need to be monitored weeklyPosted onOctober 3, 2020 6:29 pm

Dr Leleu . I do not agree to use Belantamab very late because you will not get the best of the drug. It is more logical to keep CAR T cells until the end...Posted onOctober 3, 2020 6:27 pm

Any experience with Bela Tamar in a myeloma patient who progressed into a plasma cell leukemia?Posted onOctober 3, 2020 6:24 pm

Super, top sympo and congress. Big hello from South America. We do not have access to these new drugs but we follow the advances.Posted onOctober 3, 2020 6:21 pm

Posted onOctober 3, 2020 6:21 pm

How fast is the response to Belnatamab?Posted onOctober 3, 2020 6:20 pm

Dr mateos. BCMA is rarely down regulated. Therefore, we do not really need agents to upregulate it. However, do you know if BCMA remains a relevant and useful target if you have already used and anti BCMA therapy (e.g. drug conjugates, bispecific, or car T cells ?)Posted onOctober 3, 2020 6:19 pm

Thank you sincerely. I am a patient now in remission. But I know I am not cured . I do not understand the science , but I am happy that you are discussing new drugs. We need you. Keep going.Posted onOctober 3, 2020 6:16 pm

Will this beautiful symposium available on demand? Sorry I have missed the first 30 minutes.Posted onOctober 3, 2020 6:14 pm

I have a refractory patient who received revlimid, Velcade and daratumumab. Should I use belantamab or melflufen?Posted onOctober 3, 2020 6:12 pm

Should we use selinexor before or after belamaf? Any criteria to help us to find the right sequence?Posted onOctober 3, 2020 6:08 pm

I like this interactive symposium. Well chosen topics and speakers. Please say hello to dr mohamad who always organise excellent events. Posted onOctober 3, 2020 6:07 pm

Thank you for very informative symposium. My question : when the drug Belan will be used frontline?Posted onOctober 3, 2020 6:04 pm

How many cells had to be positive to classify HR in Belantamab trials Posted onOctober 3, 2020 6:04 pm

This is a great sympo. Nice choice of format. Congratulations. Can one use belantamab as a bridge to car T cells?Posted onOctober 3, 2020 6:01 pm

Beautiful duo thank you comyPosted onOctober 3, 2020 5:53 pm

Are there any ocular diseases that preclude the use of belamafPosted onOctober 3, 2020 5:47 pm

Is belamtamab good for extramedullary disease???? Posted onOctober 3, 2020 5:45 pm

Is there any Down regulation of BCMA after Bela mad?Posted onOctober 3, 2020 5:44 pm

Any experience of belantamab after car T cells?Posted onOctober 3, 2020 5:43 pm

If I can choose in a pentarefractory patient, should we go for belantamab or bispecifcPosted onOctober 3, 2020 5:41 pm

Concerning the risk of relapse or clinical management , what is the role of the analysis of gene mutations with NGS together with the status of MRD with NGF, or NGS (analysis of VDJ)???? Posted onOctober 3, 2020 5:24 pm

It seems that there is good correlation between the results of MRD with NGS and NGF. So in clinical routine it would be not necessary to do both methods?...... or do you recommend to perform both methods in some specific cases? Posted onOctober 3, 2020 5:13 pm

IF a patient is MRD negative and he is eligible for transplant. In the COVID-19 era do you think it is best to not perform transplant and go on to maintenance therapy?Posted onOctober 3, 2020 5:05 pm

Do you think in the clinical practice to decide refarding skip or give consolidation according to MRD result? Posted onOctober 3, 2020 5:04 pm

When do you recommend to monitor MRD in transplant eligible patients?Posted onOctober 3, 2020 5:02 pm

In your clinical practice- how often you repeat PET to ensure sustained MRDPosted onOctober 3, 2020 4:52 pm

since relapses are seen even in MRD negative patients after maintenance is stopped , would that mean treatment should be continuous even in patients who remain MRD negative for a prolonged period of time ? Posted onOctober 3, 2020 4:51 pm

What about the impact of MRD in cytogenetic high risk patients? Posted onOctober 3, 2020 4:44 pm

According to presented data whether it is possible to predict MRD (-) status with triplet or quadriplet induction therapy?Posted onOctober 3, 2020 4:40 pm

At what stage of therapy is more importat to get MRD (-) status? Early or late?Posted onOctober 3, 2020 4:37 pm

Outstanding session Mohamad and panel!!! Tom M Posted onOctober 3, 2020 4:24 pm

If you give Dara-VRd induction and ASCT what is your Maint thearpy?Posted onOctober 3, 2020 4:19 pm

How long do you give maintenance therapy in 1st line? Posted onOctober 3, 2020 4:16 pm

Question to Paul. with regard to combining PI and IMiD in maintenance, where do you see Ixa-Len as a maintenance combo?Posted onOctober 3, 2020 4:07 pm

How would you optimize the treatment of induction in , young candidate patients that debuts with severe renal impairment?Posted onOctober 3, 2020 4:05 pm

How important is it to achieve a deep response prior to ASCT? is there any longer an argument to carry out ASCT in patients with Posted onOctober 3, 2020 4:02 pm

Thank you for very excellent lecture. Dr Jackson what is your suggestion for lenalidomide maintenance , 10 mg or higher. Can be use steroids with len for maintenance in high risk patients. What should be the ixa preference for maintenancePosted onOctober 3, 2020 4:00 pm

what would you give for a patient with PD on D-VRD? Posted onOctober 3, 2020 3:58 pm

Do you prefer 6 VRd vs 4 Vrd before ASCT for all?Posted onOctober 3, 2020 3:57 pm

Please how should we monitor the repons and what is the frequency of tests ? Posted onOctober 3, 2020 3:57 pm

Posted onOctober 3, 2020 3:56 pm

when will be available ESMO guidelines 2020?Posted onOctober 3, 2020 3:54 pm

Do you give double maintenance? and if so, for whom and with what?Posted onOctober 3, 2020 3:53 pm

Do you stop maintenance At 2 years treatment or until progression Posted onOctober 3, 2020 3:53 pm

Is there a way of deciding who will benefit from Len or Bortezomib therapy as maintenance ?Posted onOctober 3, 2020 3:43 pm

What do you recommend regarding REVLIMID maint. in patients post ASCT with previous other malignancyPosted onOctober 3, 2020 3:41 pm

If patient develop SPM while on revlimid, do you consider discontinuing revlimid or it depends on type of malignancy.Posted onOctober 3, 2020 3:40 pm

Were the HR patients in the maintenance phase of MM XI selected by the fact that they were still in the study after an only IMID induction? Posted onOctober 3, 2020 3:38 pm

Question to Philippe. undoubtedly ASCT upfront is beneficial overall compared to consolidation chemotherapy. Is there a subset of patients who could safely be allocated to deferred ASCT based on standard risk genetics and achieving a deep, MRD-negative response to induction?Posted onOctober 3, 2020 3:29 pm

DR MOreau: which maintenance should we use in clinical practice for patients receiving Dara VTD as induction ¿ len or dara ?Posted onOctober 3, 2020 3:26 pm

Test test test testPosted onOctober 3, 2020 3:17 pm

Posted onOctober 3, 2020 3:04 pm

Posted onOctober 3, 2020 3:04 pm

SMM of high risk: Rd or await until progression and treat him/her with an optimal schedule (inc ASCT)?Posted onOctober 3, 2020 2:55 pm

Can early intervention be actually harmful? I had two recent cases when after long stable phase, after treatment a resistant clone emerged and resulted in death.Posted onOctober 3, 2020 2:55 pm

OK. Improved now. Thank You. Posted onOctober 3, 2020 2:50 pm

ok better with live streamPosted onOctober 3, 2020 2:50 pm

there isn't audio Posted onOctober 3, 2020 2:49 pm

Stopping screen at this time!Posted onOctober 3, 2020 2:48 pm

Is this happening trouble? Just only me?Posted onOctober 3, 2020 2:46 pm

The lectures I heard fine but now at the round table there is no sound. I can see but cannot hear. Tried to exit and enter again the live stream - with no help... tried earphones as well.. no use. is this the same for others?Posted onOctober 3, 2020 2:45 pm

Hey! Can not hear sound quite!Posted onOctober 3, 2020 2:44 pm

Posted onOctober 3, 2020 2:43 pm

Sound follows witout workingPosted onOctober 3, 2020 2:43 pm

problem with the live stream? Posted onOctober 3, 2020 2:43 pm

no sound en Spain Posted onOctober 3, 2020 2:43 pm

i do not hear anythingPosted onOctober 3, 2020 2:43 pm

The livestream audio is not workingPosted onOctober 3, 2020 2:43 pm

The sound still is not working at all, it was working perfect on the pre-recorded. Not sure if everyone else is having this issue, hope this is recorded as can not hear anything Posted onOctober 3, 2020 2:42 pm

How to check low or IM genom’İç risk factors? Interval and panelPosted onOctober 3, 2020 2:42 pm

I can’t hear!Posted onOctober 3, 2020 2:42 pm

No sound to us..Posted onOctober 3, 2020 2:41 pm

we could not hear youPosted onOctober 3, 2020 2:41 pm

Posted onOctober 3, 2020 2:40 pm

we cannot hear youPosted onOctober 3, 2020 2:40 pm

SoundPosted onOctober 3, 2020 2:40 pm

You are all mute.Posted onOctober 3, 2020 2:40 pm

still can't hear them Posted onOctober 3, 2020 2:40 pm

we cann't hear please unmutePosted onOctober 3, 2020 2:39 pm

There is a problem with sound transmission. Nothing can be heard from the discussion. :( Posted onOctober 3, 2020 2:39 pm

Excuse me. No volume again. Posted onOctober 3, 2020 2:39 pm

THE SOUND DOESN´T WORKSPosted onOctober 3, 2020 2:33 pm

What do you think about the new immunotherapies for SMM?Posted onOctober 3, 2020 2:33 pm

Am I the only one having problems with sound during the round table discussion? Posted onOctober 3, 2020 2:33 pm

Posted onOctober 3, 2020 2:32 pm

No soundPosted onOctober 3, 2020 2:32 pm

Posted onOctober 3, 2020 2:32 pm

Do you think we are ready to add molecular makers to the prognostic scoring system of smoldering myeloma?Posted onOctober 3, 2020 2:32 pm

Audio does not appear to be workingPosted onOctober 3, 2020 2:32 pm

I can not hear the speaker. Are there technical issues? Posted onOctober 3, 2020 2:32 pm

Se canot hear Posted onOctober 3, 2020 2:32 pm

we have no sound Posted onOctober 3, 2020 2:32 pm

we cannot hear the speakersPosted onOctober 3, 2020 2:31 pm

We could not hear your voicePosted onOctober 3, 2020 2:31 pm

we cannot hear you, no sound! Posted onOctober 3, 2020 2:31 pm

some cannot hear youPosted onOctober 3, 2020 2:31 pm

The sound does not appear to be working, the pre-recorded lecture was perfect but since the round table there is no sound Posted onOctober 3, 2020 2:31 pm

nous ne vous entendons plus... Posted onOctober 3, 2020 2:31 pm

How do you treat a high risk SMM with severe renal disfunction? thank youPosted onOctober 3, 2020 2:24 pm

This is a question for Marivi. I totally agree with risk stratified management. However I feel uneasy about recommending treatment to a patient with 50% risk of progression at 2 years based on the current model. Because not all patients in this group are destined to progress, we risk over-treating some patients. How would you answer a patient who says they are worried that they may be unnecessarily exposed to toxicity of therapy?Posted onOctober 3, 2020 2:23 pm

How long have I to treat SMM patient if there is no progression to active MM?Posted onOctober 3, 2020 2:22 pm

How can I justify a patient without active MM to start therapy?Posted onOctober 3, 2020 2:19 pm

What about cytogenetic abberaation whether we have do it often?Posted onOctober 3, 2020 2:15 pm

Thank you, excellent talk. There are so many makers for high-risk SMM. Which one do you use most commonly, and what do you feel is the most important factor: %PCs, cytogenetics (not used in the Mayo criteria), or other factors?Posted onOctober 3, 2020 2:14 pm

How intensive we have to minitor MM smoldering patirnts&Posted onOctober 3, 2020 2:14 pm

Posted onOctober 3, 2020 1:59 pm

I would like to thanks Mohamad Mohty for opportunity to have COMY at home. RedhouanePosted onOctober 3, 2020 1:48 pm

Posted onOctober 3, 2020 1:34 pm

bonjour, comment se fait l'acces aux sessions? Posted onOctober 3, 2020 1:34 pm

hello Posted onOctober 3, 2020 1:34 pm

Posted onOctober 3, 2020 1:33 pm

Posted onOctober 3, 2020 1:30 pm

This is a testPosted onOctober 3, 2020 1:28 pm

Posted onOctober 3, 2020 1:09 pm

Posted onOctober 3, 2020 1:02 pm

Posted onOctober 3, 2020 1:02 pm

testing 123Posted onOctober 3, 2020 12:23 pm

Test questionPosted onOctober 3, 2020 10:25 am

NicePosted onOctober 2, 2020 6:09 pm

Hello there guysPosted onOctober 2, 2020 6:09 pm

Hi therePosted onOctober 2, 2020 6:08 pm

HiPosted onOctober 2, 2020 6:05 pm

HelloPosted onOctober 2, 2020 6:05 pm